← Leaderboards
Colleen M Hadigan
Massachusetts General Hospital
$2,621,754
Attributed
$3,600,850
Total exposure
14
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $685.3K · FY2005–17$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$3,600,850 · 14
By mechanism
U01$1,958,193 · 1
K23$648,354 · 1
M01$509,589 · 11
R21$484,714 · 1
Top collaborators
- Steven Kyle Grinspoon3 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Steven Kyle Grinspoon$75,757,679
- Takara Leah Stanley$7,360,441
- Kathleen Elizabeth Corey$4,109,943
- Elizabeth K Speliotes$12,106,253
- Martin Torriani$2,535,105
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsHuman SubjectLipodystrophyClinical ResearchHuman Therapy EvaluationAdipose TissueMetabolism Disorder ChemotherapyGlucose Clamp TechniqueFree Fatty AcidsBody CompositionInsulin Sensitivity /ResistanceGlucose MetabolismPathologic ProcessMetforminPatient Oriented ResearchResearch PersonnelTriglyceridesGrantUnited States National Institutes Of HealthGender DifferenceSex HormonesLiverChronicInsulin Sensitivity
Grant awards (23)
Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative U01 Grant$685,269
U01 · FY2017 · AI
Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative U01 Grant$685,269
U01 · FY2016 · AI
Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative U01 Grant$587,655
U01 · FY2015 · AI
HEPATIC STEATOSIS AND INSULIN IN HIV PATIENTS$18,994
M01 · FY2007 · RR · contact PI
ANTI-LIPOLYTIC STRATEGY FOR HIV LIPODYSTROPHY$16,886
M01 · FY2007 · RR · contact PI
HEPATIC STEATOSIS AND INSULIN IN HIV PATIENTS$94,289
M01 · FY2006 · RR · contact PI
ANTI-LIPOLYTIC STRATEGY FOR HIV LIPODYSTROPHY$60,924
M01 · FY2006 · RR · contact PI
FDG/PET IMAGING FOR THE EVALUATION OF GLUCOSE METABOLISM IN HIV LIPODYSTROPHY$1,449
M01 · FY2006 · RR · contact PI
ANTI-LIPOLYTIC STRATEGY FOR HIV LIPODYSTROPHY$138,208
M01 · FY2005 · RR
FDG/PET IMAGING FOR THE EVALUATION OF GLUCOSE METABOLISM IN HIV LIPODYSTROPHY$50,390
M01 · FY2005 · RR
HEPATIC STEATOSIS AND INSULIN IN HIV PATIENTS$28,795
M01 · FY2005 · RR
PIOGLITAZONE FOR HEPATIC STEATOSIS IN HIV/HCV CO-INFECTION$2,881
M01 · FY2005 · RR
INSULIN RESISTANCE IN THE HIV LIPODYSTROPHY SYNDROME$129,285
K23 · FY2004 · DK
ANTI-LIPOLYTIC STRATEGY FOR HIV LIPODYSTROPHY$82,948
M01 · FY2004 · RR
FDG/PET IMAGING FOR THE EVALUATION OF GLUCOSE METABOLISM$9,214
M01 · FY2004 · RR
DIETARY FIBER FOR THE TREATMENT OF HYPERLIPIDEMIA IN HIV-ASSOCIATED LIPODYS$4,611
M01 · FY2004 · RR
Anti-lipolytic Therapy for HIV Lipodystrophy$243,087
R21 · FY2003 · HL
INSULIN RESISTANCE IN THE HIV LIPODYSTROPHY SYNDROME$131,031
K23 · FY2003 · DK
Anti-lipolytic Therapy for HIV Lipodystrophy$241,627
R21 · FY2002 · HL
INSULIN RESISTANCE IN THE HIV LIPODYSTROPHY SYNDROME$129,327
K23 · FY2002 · DK
INSULIN RESISTANCE IN THE HIV LIPODYSTROPHY SYNDROME$129,535
K23 · FY2001 · DK
INSULIN RESISTANCE IN THE HIV LIPODYSTROPHY SYNDROME$129,176
K23 · FY2000 · DK
AIDS wasting in women: Anabolic effects of testosterone treatment only$0
M01 · FY2000 · RR